Evidence map›Paper›PMID 38140576›Full record

ArticleViruses2023

Characterization of the Cynomolgus Macaque Model of Marburg Virus Disease and Assessment of Timing for Therapeutic Treatment Testing.

Elizabeth E Zumbrun, Carly B Garvey, Jay B Wells, Ginger C Lynn, Sean Van Tongeren, Jesse T Steffens, Kelly S Wetzel, Laura M Gomba, Kristan A O'Brien, Franco D Rossi and 19 more

Open access · goldAbstract read
In one paragraph

Article in Viruses, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors at 3 institutions in 1 country.

Elizabeth E ZumbrunUnited States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Carly B GarveyUnited States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.ORCID 0009-0009-2481-8900
Jay B WellsUnited States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Ginger C LynnUnited States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Sean Van TongerenUnited States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Jesse T SteffensUnited States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Kelly S WetzelUnited States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Laura M GombaUnited States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Kristan A O'BrienUnited States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Franco D RossiUnited States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Xiankun ZengUnited States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Eric D LeeUnited States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Jo Lynne W RaymondUnited States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Diana A HoffmanUnited States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Alexandra N JayUnited States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Elizabeth S BrownUnited States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Paul A KallgrenUnited States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
Sarah L NorrisUnited States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.ORCID 0000-0002-5393-6430
Jean Cantey-KiserPharPoint, Wilmington, NC 28405, USA.
Humza KudiyaGilead Sciences, Foster City, CA 94404, USA.
Chris ArthurGilead Sciences, Foster City, CA 94404, USA.
Christiana BlairGilead Sciences, Foster City, CA 94404, USA.
Darius BabusisGilead Sciences, Foster City, CA 94404, USA.ORCID 0000-0001-5599-1671
Victor C ChuGilead Sciences, Foster City, CA 94404, USA.
Bali SinghGilead Sciences, Foster City, CA 94404, USA.
Roy BannisterGilead Sciences, Foster City, CA 94404, USA.
Danielle P PorterGilead Sciences, Foster City, CA 94404, USA.
Tomas CihlarGilead Sciences, Foster City, CA 94404, USA.
John M DyeUnited States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
United States Army Medical Research Institute of Infectious Diseases · USGilead Sciences (United States) · USWilmington University · US

Funding

t Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) W81XWH-16-0472
6 · The paper itself

Abstract

Marburg virus (MARV) causes severe disease and high mortality in humans. The objective of this study was to characterize disease manifestations and pathogenesis in cynomolgus macaques exposed to MARV. The results of this natural history study may be used to identify features of MARV disease useful in defining the ideal treatment initiation time for subsequent evaluations of investigational therapeutics using this model. Twelve cynomolgus macaques were exposed to a target dose of 1000 plaque-forming units MARV by the intramuscular route, and six control animals were mock-exposed. The primary endpoint of this study was survival to Day 28 post-inoculation (PI). Anesthesia events were minimized with the use of central venous catheters for periodic blood collection, and temperature and activity were continuously monitored by telemetry. All mock-exposed animals remained healthy for the duration of the study. All 12 MARV-exposed animals (100%) became infected, developed illness, and succumbed on Days 8-10 PI. On Day 4 PI, 11 of the 12 MARV-exposed animals had statistically significant temperature elevations over baseline. Clinically observable signs of MARV disease first appeared on Day 5 PI, when 6 of the 12 animals exhibited reduced responsiveness. Ultimately, systemic inflammation, coagulopathy, and direct cytopathic effects of MARV all contributed to multiorgan dysfunction, organ failure, and death or euthanasia of all MARV-exposed animals. Manifestations of MARV disease, including fever, systemic viremia, lymphocytolysis, coagulopathy, and hepatocellular damage, could be used as triggers for initiation of treatment in future therapeutic efficacy studies.

Indexed as

MarburgvirusMarburg Virus DiseaseAnimalsHumansLiverMacaca fascicularisViremiaanimal modelanimal rulecynomolgus macaquefilovirusintramuscularMarburg virusnonhuman primatepathogenesistelemetry

Identifiers

PMID38140576
PMCPMC10748006
OpenAlexW4389100017

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.